ATE334131T1 - Triazolopyridine als entzündungshemmende verbindungen - Google Patents

Triazolopyridine als entzündungshemmende verbindungen

Info

Publication number: ATE334131T1
Authority: AT; Austria
Prior art keywords: sup; sub; alkyl; hydrogen; group
Prior art date: 2003-02-14

Application number

AT04707599T

Other languages

English (en)

Inventor

John Frederick Braganza

Michael Anthony Letavic

Kim Francis Mcclure

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-14

Filing date

2004-02-03

Publication date

2006-08-15

2004-02-03 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-08-15 Application granted granted Critical

2006-08-15 Publication of ATE334131T1 publication Critical patent/ATE334131T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 2
150000008523 triazolopyridines Chemical class 0.000 title abstract 2
230000003110 anti-inflammatory effect Effects 0.000 title 1
125000001424 substituent group Chemical group 0.000 abstract 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
208000023275 Autoimmune disease Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
102000043136 MAP kinase family Human genes 0.000 abstract 1
108091054455 MAP kinase family Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
208000028867 ischemia Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
201000008482 osteoarthritis Diseases 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
230000010410 reperfusion Effects 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Neurology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Cardiology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)

AT04707599T 2003-02-14 2004-02-03 Triazolopyridine als entzündungshemmende verbindungen ATE334131T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US44778703P	2003-02-14	2003-02-14

Publications (1)

Publication Number	Publication Date
ATE334131T1 true ATE334131T1 (de)	2006-08-15

Family

ID=32869645

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04707599T ATE334131T1 (de)	2003-02-14	2004-02-03	Triazolopyridine als entzündungshemmende verbindungen

Country Status (10)

Country	Link
US (1)	US7321040B2 (de)
EP (1)	EP1601672B1 (de)
JP (1)	JP2006517580A (de)
AT (1)	ATE334131T1 (de)
BR (1)	BRPI0407384A (de)
CA (1)	CA2515190A1 (de)
DE (1)	DE602004001676T2 (de)
ES (1)	ES2264795T3 (de)
MX (1)	MXPA05008568A (de)
WO (1)	WO2004072072A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005273612B2 (en) *	2004-08-12	2010-10-14	Pfizer Inc.	Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
MX2007002050A (es) *	2004-08-18	2007-03-29	Pharmacia & Upjohn Co Llc	Compuestos de triazolopiridina.
JP2008509985A (ja) *	2004-08-18	2008-04-03	ファルマシアアンドアップジョンカンパニーリミテッドライアビリティカンパニー	炎症治療用の新規トリアゾロピリジン化合物
US7572807B2 (en) *	2005-06-09	2009-08-11	Bristol-Myers Squibb Company	Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) *	2005-06-09	2009-08-25	Bristol-Myers Squibb Company	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
JPWO2007063868A1 (ja) *	2005-11-29	2009-05-07	東レ株式会社	アリールメチレンウレア誘導体及びその用途
EP1984363A1 (de) *	2006-02-09	2008-10-29	Pfizer Limited	Triazolopyridinverbindungen
US20090192164A1 (en) *	2006-06-28	2009-07-30	Aska Pharmaceutical Co., Ltd.	Treating agent of inflammatory bowel disease
EP1894931A1 (de) *	2006-08-30	2008-03-05	Cellzome Ag	Triazol-Derivate verwendbar als Kinase-Inhibitoren
JP5336375B2 (ja) *	2006-08-30	2013-11-06	セルゾームリミテッド	キナーゼ阻害剤としてのトリアゾール誘導体
KR101434706B1 (ko)	2007-02-16	2014-08-26	아스카 세이야쿠 가부시키가이샤	미립자 유성 현탁액을 포함하는 의약 조성물
JP2010523725A (ja)	2007-04-16	2010-07-15	レオファーマアクティーゼルスカブ	皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン
WO2009005675A1 (en)	2007-06-28	2009-01-08	Abbott Laboratories	Novel triazolopyridazines
CA2691448A1 (en)	2007-08-31	2009-03-05	Dominique Swinnen	Triazolopyridine compounds and their use as ask inhibitors
US8119658B2 (en) *	2007-10-01	2012-02-21	Bristol-Myers Squibb Company	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
GB0719803D0 (en)	2007-10-10	2007-11-21	Cancer Rec Tech Ltd	Therapeutic compounds and their use
UA102828C2 (en)	2007-11-27	2013-08-27	Целльзом Лимитед	Amino triazoles as p13k inhibitors
JO3041B1 (ar)	2008-07-25	2016-09-05	Galapagos Nv	مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010184A1 (en) *	2008-07-25	2010-01-28	Galapagos Nv	[1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
BRPI1005327A2 (pt)	2009-02-17	2019-09-24	Chiesi Farm Spa	derivados de triazolopiridina como inibidores de p38 map quinase
TWI462920B (zh)	2009-06-26	2014-12-01	葛萊伯格有限公司	用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar)	2009-06-26	2016-09-05	Galapagos Nv	مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
GB201009731D0 (en) *	2010-06-10	2010-07-21	Pulmagen Therapeutics Inflamma	Kinase inhibitors
DK2734205T3 (en) *	2011-07-21	2018-06-14	Tolero Pharmaceuticals Inc	Heterocyclic Protein Kinase Inhibitors
MY167216A (en) *	2011-12-09	2018-08-14	Chiesi Farm Spa	Kinase inhibitors
BR112014013178A2 (pt)	2011-12-09	2017-06-13	Chiesi Farm Spa	composto, composição farmacêutica e uso de um composto
SG11201402985VA (en) *	2011-12-09	2014-08-28	Chiesi Farma Spa	Kinase inhibitors
EP2875014B1 (de)	2012-07-17	2017-11-29	Washington University	Schleimlösungsarzneien und verwendungen dafür
RU2015151886A (ru)	2013-06-06	2017-06-08	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Ингибиторы киназ
GB201402071D0 (en)	2014-02-07	2014-03-26	Galapagos Nv	Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en)	2014-02-07	2014-03-26	Galapagos Nv	Pharmaceutical compositions for the treatment of inflammatory disorders
GB201511382D0 (en)	2015-06-29	2015-08-12	Imp Innovations Ltd	Novel compounds and their use in therapy
ES2927715T3 (es)	2017-10-05	2022-11-10	Fulcrum Therapeutics Inc	Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
GB201808575D0 (en)	2018-05-24	2018-07-11	Galapagos Nv	Methods for the treatment of psoriatic arthrits
HUE072069T2 (hu)	2019-02-12	2025-10-28	Sumitomo Pharma America Inc	2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
CN114031619A (zh) *	2021-12-17	2022-02-11	山东汇海医药化工有限公司	一种图卡替尼中间体的制备方法
CN119997982A (zh)	2022-09-09	2025-05-13	迈里克斯制药有限公司	包含nmt抑制剂的抗体药物偶联物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3050525A (en) *	1960-12-14	1962-08-21	John B Bicking	Certain derivatives of s-triazolo [4, 3-a]-pyridine
BE640616A (de) *	1962-12-19
US3492397A (en) *	1967-04-07	1970-01-27	Warner Lambert Pharmaceutical	Sustained release dosage in the pellet form and process thereof
US4060598A (en) *	1967-06-28	1977-11-29	Boehringer Mannheim G.M.B.H.	Tablets coated with aqueous resin dispersions
US3538214A (en) *	1969-04-22	1970-11-03	Merck & Co Inc	Controlled release medicinal tablets
US4173626A (en) *	1978-12-11	1979-11-06	Merck & Co., Inc.	Sustained release indomethacin
US5716972A (en) *	1993-01-13	1998-02-10	Smithkline Beecham Corporation	Pyridyl substituted imidazoles
EP1306377A3 (de) *	1993-11-08	2003-05-07	Smithkline Beecham Corporation	Pyridyl-Oxazole und ihre Verwendung als Cytokine-Inhibitoren
ZA97175B (en) *	1996-01-11	1997-11-04	Smithkline Beecham Corp	Novel substituted imidazole compounds.
US6207687B1 (en)	1998-07-31	2001-03-27	Merck & Co., Inc.	Substituted imidazoles having cytokine inhibitory activity
US6350744B1 (en) *	1998-11-20	2002-02-26	Merck & Co., Inc.	Compounds having cytokine inhibitory activity
EP1140083A4 (de) *	1999-01-08	2004-01-02	Smithkline Beecham Corp	Neue verbindungen
EP2298311B1 (de)	1999-01-13	2012-05-09	Bayer HealthCare LLC	Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer
CO5170501A1 (es)	1999-04-14	2002-06-27	Novartis Ag	AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
ES2290115T3 (es) *	2000-02-01	2008-02-16	ABBOTT GMBH & CO. KG	Compuestos heterociclicos y su aplicacion como inhibidores de parp.
WO2002072576A1 (en)	2001-03-09	2002-09-19	Pfizer Products Inc.	Benzimidazole anti-inflammatory compounds
OA12552A (en) *	2001-03-09	2006-06-06	Pfizer Prod Inc	Triazolopyridines as anti-inflammatory agents.
ATE304009T1 (de)	2001-04-04	2005-09-15	Pfizer Prod Inc	Neue benzotriazole mit entzündungshemmender wirkung
US6921762B2 (en) *	2001-11-16	2005-07-26	Amgen Inc.	Substituted indolizine-like compounds and methods of use
US7012143B2 (en) *	2002-08-30	2006-03-14	Dombroski Mark A	Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7037923B2 (en) *	2002-08-30	2006-05-02	Pfizer, Inc.	Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
AU2003268353A1 (en)	2002-08-30	2004-03-19	Tufts University	Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
PA8579601A1 (es) *	2002-08-30	2004-05-07	Pfizer Prod Inc	Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US20040092547A1 (en) *	2002-08-30	2004-05-13	Pfizer Inc	Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
JP2006508914A (ja) *	2002-08-30	2006-03-16	ファイザー・プロダクツ・インク	トリアゾロ−ピリジン製造のための新規な方法および中間体

2004
- 2004-02-03 EP EP04707599A patent/EP1601672B1/de not_active Expired - Lifetime
- 2004-02-03 MX MXPA05008568A patent/MXPA05008568A/es unknown
- 2004-02-03 DE DE602004001676T patent/DE602004001676T2/de not_active Expired - Fee Related
- 2004-02-03 AT AT04707599T patent/ATE334131T1/de not_active IP Right Cessation
- 2004-02-03 BR BRPI0407384-3A patent/BRPI0407384A/pt not_active IP Right Cessation
- 2004-02-03 JP JP2006502428A patent/JP2006517580A/ja not_active Withdrawn
- 2004-02-03 WO PCT/IB2004/000363 patent/WO2004072072A1/en not_active Ceased
- 2004-02-03 ES ES04707599T patent/ES2264795T3/es not_active Expired - Lifetime
- 2004-02-03 CA CA002515190A patent/CA2515190A1/en not_active Abandoned
- 2004-02-11 US US10/776,953 patent/US7321040B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MXPA05008568A (es)	2005-11-04
BRPI0407384A (pt)	2006-02-21
US20050075365A1 (en)	2005-04-07
DE602004001676T2 (de)	2007-08-30
DE602004001676D1 (de)	2006-09-07
JP2006517580A (ja)	2006-07-27
ES2264795T3 (es)	2007-01-16
WO2004072072A1 (en)	2004-08-26
CA2515190A1 (en)	2004-08-26
EP1601672B1 (de)	2006-07-26
EP1601672A1 (de)	2005-12-07
US7321040B2 (en)	2008-01-22

Legal Events

Date	Code	Title	Description
2007-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE602004001676D1 (de)	2006-09-07	Triazolopyridine als entzündungshemmende verbindungen
KR102670486B1 (ko)	2024-05-28	마크로사이클릭 면역조절제
CA2440222A1 (en)	2002-09-19	Triazolopyridines as anti-inflammatory agents
TWI758300B (zh)	2022-03-21	免疫調節劑化合物
KR102647257B1 (ko)	2024-03-13	면역조절제 화합물
ES2598503T3 (es)	2017-01-27	Nuevos citostáticos nucleósidos 7-deazapurina
ES2716811T3 (es)	2019-06-17	Derivados piperidinopirimidínicos para el tratamiento de infecciones víricas
RU2165429C2 (ru)	2001-04-20	Липидные сложные эфиры нуклеозидмонофосфатов, обладающие противоопухолевой активностью, способ их получения и лекарственное средство
AP2002002460A0 (en)	2002-06-30	Novel benzimidazole anti-inflammatory compounds.
ES2707885T3 (es)	2019-04-05	Alquilpirimidinderivados para el tratamiento de infecciones víricas y otras enfermedades
ES3064674T3 (en)	2026-04-28	Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
CA2379903A1 (en)	2002-10-04	Novel benzotriazoles anti-inflammatory compounds
KR102890201B1 (ko)	2025-11-24	Pd-l1 억제제로서의 인단
US20030144502A1 (en)	2003-07-31	Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides
MXPA05005282A (es)	2005-07-25	Derivados de nucleosido antiviral.
PT821690E (pt)	2012-09-17	Análogos de nucleotídeos para tratamento de infeções virais
KR900012926A (ko)	1990-09-03	카르보스티릴 유도체
KR940703841A (ko)	1994-12-12	5-o-데소사미닐에리쓰로노라이드 유도체
WO1996011200A1 (en)	1996-04-18	Purine and guanine compounds as inhibitors of pnp
ES2920888T3 (es)	2022-08-11	Derivado de sulfonamida y método de preparación y uso del mismo
WO2010027424A2 (en)	2010-03-11	9-substituted phenanthrene based tylophorine derivatives
EP1885722A4 (de)	2010-02-24	Chinolinderivate als ep4-antagonisten
WO2004020438A3 (en)	2004-07-22	Novel processes and intermediates for preparing triazolo-pyridines
Junlong et al.	2023	Discovery and bioassay of disubstituted β-elemene-NO donor conjugates: synergistic enhancement in the treatment of leukemia
EP1409486A1 (de)	2004-04-21	Pyridopyridopyrrolopyrroloindol- und pyridopyrrolopyrrolocarbazolderivate, verfahren zu deren herstellung und diese derivate enthaltende pharmazeutische zusammensetzungen